Kangmei Pharmaceutical Co Ltd (600518) - Total Liabilities
Based on the latest financial reports, Kangmei Pharmaceutical Co Ltd (600518) has total liabilities worth CN¥6.46 Billion CNY (≈ $945.05 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Kangmei Pharmaceutical Co Ltd operating cash flow efficiency to assess how effectively this company generates cash.
Kangmei Pharmaceutical Co Ltd - Total Liabilities Trend (1997–2024)
This chart illustrates how Kangmei Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Kangmei Pharmaceutical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Kangmei Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Kangmei Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Interstate BancSystem Inc
NASDAQ:FIBK
|
USA | $23.19 Billion |
|
GQG Partners Inc
AU:GQG
|
Australia | AU$50.29 Million |
|
Enaex S.A
SN:ENAEX
|
Chile | CL$1.12 Billion |
|
Shikun & Binui
TA:SKBN
|
Israel | ILA19.56 Billion |
|
QL Resources Bhd
KLSE:7084
|
Malaysia | RM2.34 Billion |
|
COFCO Capital Holdings Co Ltd
SHE:002423
|
China | CN¥140.48 Billion |
|
Tian Di Science & Technology Co Ltd
SHG:600582
|
China | CN¥26.42 Billion |
|
Viohalco S.A
BR:VIO
|
Belgium | €-2.36 Billion |
Liability Composition Analysis (1997–2024)
This chart breaks down Kangmei Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600518 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kangmei Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kangmei Pharmaceutical Co Ltd (1997–2024)
The table below shows the annual total liabilities of Kangmei Pharmaceutical Co Ltd from 1997 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥6.59 Billion ≈ $964.17 Million |
-8.49% |
| 2023-12-31 | CN¥7.20 Billion ≈ $1.05 Billion |
-12.03% |
| 2022-12-31 | CN¥8.18 Billion ≈ $1.20 Billion |
+34.49% |
| 2021-12-31 | CN¥6.09 Billion ≈ $890.54 Million |
-86.09% |
| 2020-12-31 | CN¥43.74 Billion ≈ $6.40 Billion |
-0.45% |
| 2019-12-31 | CN¥43.94 Billion ≈ $6.43 Billion |
-6.58% |
| 2018-12-31 | CN¥47.03 Billion ≈ $6.88 Billion |
+27.87% |
| 2017-12-31 | CN¥36.78 Billion ≈ $5.38 Billion |
+44.56% |
| 2016-12-31 | CN¥25.44 Billion ≈ $3.72 Billion |
+32.04% |
| 2015-12-31 | CN¥19.27 Billion ≈ $2.82 Billion |
+72.63% |
| 2014-12-31 | CN¥11.16 Billion ≈ $1.63 Billion |
+9.19% |
| 2013-12-31 | CN¥10.22 Billion ≈ $1.50 Billion |
+38.59% |
| 2012-12-31 | CN¥7.38 Billion ≈ $1.08 Billion |
+23.14% |
| 2011-12-31 | CN¥5.99 Billion ≈ $876.41 Million |
+82.46% |
| 2010-12-31 | CN¥3.28 Billion ≈ $480.33 Million |
+68.75% |
| 2009-12-31 | CN¥1.95 Billion ≈ $284.64 Million |
+50.50% |
| 2008-12-31 | CN¥1.29 Billion ≈ $189.13 Million |
+46.42% |
| 2007-12-31 | CN¥882.71 Million ≈ $129.17 Million |
+15.19% |
| 2006-12-31 | CN¥766.30 Million ≈ $112.13 Million |
+254.03% |
| 2005-12-31 | CN¥216.45 Million ≈ $31.67 Million |
-36.73% |
| 2004-12-31 | CN¥342.09 Million ≈ $50.06 Million |
+30.44% |
| 2003-12-31 | CN¥262.25 Million ≈ $38.38 Million |
+10.03% |
| 2002-12-31 | CN¥238.35 Million ≈ $34.88 Million |
+56.28% |
| 2001-12-31 | CN¥152.51 Million ≈ $22.32 Million |
+19.83% |
| 2000-12-31 | CN¥127.27 Million ≈ $18.62 Million |
+9.93% |
| 1999-12-31 | CN¥115.77 Million ≈ $16.94 Million |
-11.71% |
| 1998-12-31 | CN¥131.12 Million ≈ $19.19 Million |
+15.45% |
| 1997-12-31 | CN¥113.58 Million ≈ $16.62 Million |
-- |
About Kangmei Pharmaceutical Co Ltd
Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. In addition, it engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical … Read more